Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Article 2009 en
Authors
BF
Bengt Fellström
AJ
Alan G. Jardine
RS
Roland E. Schmieder
Abstract
1 min read
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)
W. P. T. James, Ian D. Caterson, Walmir Coutinho, Nick Finer, Luc F. Van Gaal, Aldo Maggioni, Christian Torp‐Pedersen, Arya M. Sharma, Gillian Shepherd, Richard A. Rode, Cheryl Renz
Björn Redfors, Shmuel Chen, Aaron Crowley, Ori Ben‐Yehuda, Bernard J. Gersh, Nicholas Lembo, W. Morris Brown, Adrian Banning, David P. Taggart, Patrick W. Serruys, A. Pieter Kappetein, Joseph F. Sabik, Gregg W. Stone
Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White, Patrick W. Serruys, Philippe Gabríel Steg, Judith S. Hochman, Aldo P. Maggioni, Christoph Bode, Donald W. Weaver, Joel L. Johnson, Greg Cicconetti, Mary Ann Lukas, Elizabeth Tarka, Christopher P. Cannon
David E. Kandzari, Anthony Gershlick, Patrick W. Serruys, Martin B. Leon, Marie‐Claude Morice, Charles A. Simonton, Nicholas Lembo, Adrian Banning, Béla Merkely, Ad J. van Boven, Imre Ungi, A. Pieter Kappetein, Joseph F. Sabik, Philippe Généreux, Ovidiu Dressler, Gregg W. Stone
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.